Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: A strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy

Oncotarget

Volumn 5, Issue 20, 2014, Pages 9889-9900

  Martino Echarri, Estefania ^a   Henderson, Beric R ^a   Brocardo, Mariana G ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

5 fluorouracil; APC; Chk1 inhibitors; Colon cancer; DNA replication checkpoint

Indexed keywords

5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; APC PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; FLUOROURACIL; HISTONE H2AX; MK 8776; PROTEIN SERINE THREONINE KINASE INHIBITOR; RABUSERTIB; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DNA; PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DNA REPLICATION; DNA REPLICATION CHECKPOINT; DRUG POTENTIATION; DRUG SENSITIVITY; G1 PHASE CELL CYCLE CHECKPOINT; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT; ADENOMATOUS POLYPOSIS COLI; BIOSYNTHESIS; CACO 2 CELL LINE; COLORECTAL NEOPLASMS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HCT116 CELL LINE; HEK293 CELL LINE; HT 29 CELL LINE; METABOLISM; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ADENOMATOUS POLYPOSIS COLI; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CACO-2 CELLS; COLORECTAL NEOPLASMS; DNA REPLICATION; DNA, NEOPLASM; DRUG SYNERGISM; FLUOROURACIL; GENES, APC; HCT116 CELLS; HEK293 CELLS; HT29 CELLS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 84924583833     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2475     Document Type: Article

References (35)

1. Kanwar SS, Poolla A and Majumdar AP. Regulation of colon cancer recurrence and development of therapeutic strategies. World J Gastrointest Pathophysiol. 2012; 3(1):1-9.
2. Rao CV and Yamada HY. Genomic instability and colon carcinogenesis: from the perspective of genes. Front Oncol. 2013; 3:130.
3. Polakis P. Wnt signaling and cancer. Genes & Development. 2000; 14(15):1837-1851.
4. Senda T, Iizuka-Kogo A, Onouchi T and Shimomura A. Adenomatous polyposis coli (APC) plays multiple roles in the intestinal and colorectal epithelia. Med Mol Morphol. 2007; 40(2):68-81.
5. Fodde R, Smits R and Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nature Reviews Cancer. 2001; 1(1):55-67.
6. Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M and Warusavitarne J. Molecular pathways in colorectal cancer. Journal of Gastroenterology & Hepatology. 2012; 27(9):1423-1431.
7. Brocardo M and Henderson BR. APC shuttling to the membrane, nucleus and beyond. Trends Cell Biol. 2008; 18(12):587-596.
8. Lui C, Mills K, Brocardo MG, Sharma M and Henderson BR. APC as a mobile scaffold: regulation and function at the nucleus, centrosomes, and mitochondria. IUBMB Life. 2011; 64(3):209-214.
9. Lesko AC, Goss KH and Prosperi JR. Exploiting APC function as a novel cancer therapy. Curr Drug Targets. 2014 15(1):90-102.
10. Brocardo MG, Borowiec JA and Henderson BR. Adenomatous polyposis coli protein regulates the cellular response to DNA replication stress. Int J Biochem Cell Biol. 2011; 43(9):1354-1364.
11. Longley DB, Harkin DP and Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer. 2003; 3(5):330-338.
12. Feijoo C, Hall-Jackson C, Wu R, Jenkins D, Leitch J, Gilbert DM and Smythe C. Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol. 2001; 154(5):913-923.
13. McNeely S, Beckmann R and Bence Lin AK. CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy. Pharmacol Ther. 2014;142(1):1-10.
14. Ma CX, Janetka JW and Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med. 2011; 17(2):88-96.
15. Montano R, Chung I, Garner KM, Parry D and Eastman A. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther. 2012; 11(2):427-438.
16. Kemp MG, Akan Z, Yilmaz S, Grillo M, Smith-Roe SL, Kang T-H, Cordeiro-Stone M, Kaufmann WK, Abraham RT, Sancar A and Unsal-Kacmaz K. Tipin-replication protein A interaction mediates Chk1 phosphorylation by ATR in response to genotoxic stress. J Biol Chem. 2010; 285(22):16562-16571.
17. Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T and Hashimoto-Tamaoki T. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Research. 2001; 61(3):1029-1037.
18. O'Connell MJ and Cimprich KA. G2 damage checkpoints: what is the turn-on? Journal of Cell Science. 2005; 118(Pt 1):1-6.
19. Zilberberg A, Lahav L and Rosin-Arbesfeld R. Restoration of APC gene function in colorectal cancer cells by aminoglycoside- and macrolide-induced read-through of premature termination codons. Gut. 2010;59(4):496-507.
20. Xiao Z, Xue J, Sowin TJ, Rosenberg SH and Zhang H. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene. 2005; 24(8):1403-1411.
21. Gagou ME, Zuazua-Villar P and Meuth M. Enhanced H2AX phosphorylation, DNA replication fork arrest, and cell death in the absence of Chk1. Mol Biol Cell. 2010; 21(5):739-752.
22. Montano R, Thompson R, Chung I, Hou H, Khan N and Eastman A. Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo. BMC Cancer. 2013; 13:604.
23. Guzi TJ, Paruch K, Dwyer MP, Labroli M, Shanahan F, Davis N, Taricani L, Wiswell D, Seghezzi W, Penaflor E, Bhagwat B, Wang W, Gu D, Hsieh Y, Lee S, Liu M, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011; 10(4):591-602.
24. Schenk EL, Koh BD, Flatten KS, Peterson KL, Parry D, Hess AD, Smith BD, Karp JE, Karnitz LM and Kaufmann SH. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro. Clinical Cancer Research. 2012; 18(19):5364-5373.
25. Cho SH, Toouli CD, Fujii GH, Crain C and Parry D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle. 2005; 4(1):131-139.
26. Xiao Z, Xue J, Sowin TJ and Zhang H. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther. 2006; 5(8):1935-1943.
27. Narayan S, Jaiswal AS and Balusu R. Tumor suppressor APC blocks DNA polymerase beta-dependent strand displacement synthesis during long patch but not short patch base excision repair and increases sensitivity to methylmethane sulfonate. J Biol Chem. 2005; 280(8):6942-6949.
28. Kim JC, Roh SA, Cho DH, Kim TW, Yoon SN, Kim CW, Yu CS, Kim SY and Kim YS. Chemoresponsiveness associated with canonical molecular changes in colorectal adenocarcinomas. Anticancer Res. 2009; 29(8):3115-3123.
29. Fujinaka Y, Matsuoka K, Iimori M, Tuul M, Sakasai R, Yoshinaga K, Saeki H, Morita M, Kakeji Y, Gillespie DA, Yamamoto K, Takata M, Kitao H and Maehara Y. ATR-Chk1 signaling pathway and homologous recombinational repair protect cells from 5-fluorouracil cytotoxicity. DNA Repair (Amst). 2012;11(3):247-258.
30. Schneikert J and Behrens J. Truncated APC is required for cell proliferation and DNA replication. International Journal of Cancer. 2006; 119(1):74-79.
31. Kaeser MD, Pebernard S and Iggo RD. Regulation of p53 stability and function in HCT116 colon cancer cells. J Biol Chem. 2004; 279(9):7598-7605.
32. Sun XX, Dai MS and Lu H. 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J Biol Chem. 2007; 282(11):8052-8059.
33. Greenow KR, Clarke AR and Jones RH. Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation. Oncogene. 2009; 28(11):1443-1453.
34. Brocardo M, Lei Y, Tighe A, Taylor SS, Mok MT and Henderson BR. Mitochondrial targeting of adenomatous polyposis coli protein is stimulated by truncating cancer mutations: regulation of Bcl-2 and implications for cell survival. J Biol Chem. 2008; 283(9):5950-5959.
35. Boyd SD, Tsai KY and Jacks T. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat Cell Biol. 2000; 2(9):563-568.